Blog
RSS FeedPosted by Michael Wonder on 23 Nov 2017
Roche’s Erivedge no longer funded by the NHS
23 November 2017 - Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment ...
Posted by Michael Wonder on 20 Nov 2017
Bayer’s Stivarga wins NICE approval for GIST
20 November 2017 - Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a ...
Posted by Michael Wonder on 16 Nov 2017
Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance
16 November 2017 - NICE has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave ...
Posted by Michael Wonder on 13 Nov 2017
NICE ‘no’ for short bowel syndrome drug Revestive
13 November 2017 - UK medicines cost-effectiveness watchdog NICE has published draft guidance today that does not recommend Revestive (teduglutide) ...
Posted by Michael Wonder on 10 Nov 2017
NICE recommends Mavenclad (cladribine tablets) for highly active multiple sclerosis
9 November 2017 - First multiple sclerosis therapy to achieve positive NICE recommendation in the shortest possible timeframe. ...
Posted by Michael Wonder on 09 Nov 2017
NICE turns down Bayer’s Stivarga for liver cancer
8 November 2017 - Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced ...
Posted by Michael Wonder on 02 Nov 2017
Final NICE nod for Sanofi’s Kevzara
2 November 2017 - The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as ...
Posted by Michael Wonder on 23 Oct 2017
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
23 October 2017 - NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar ...
Posted by Michael Wonder on 23 Oct 2017
GSK wins U.S. shingles vaccine approval, UK nod for gene therapy
23 October 2017 - GlaxoSmithKline has won U.S. approval for a new and improved shingles vaccine, the second of three ...
Posted by Michael Wonder on 23 Oct 2017
NICE approves gene therapy for rare ‘bubble baby syndrome’
23 October 2017 - Strimvelis, a treatment for an ultra-rare inherited immune deficiency condition that has been dubbed ‘bubble baby syndrome’ ...
Posted by Michael Wonder on 23 Oct 2017
NHS to fund gene therapy for 'bubble babies'
23 October 2017 - The NHS will fund gene therapy for the first time, with a £500,000 treatment for “bubble ...
Posted by Michael Wonder on 20 Oct 2017
NICE no for Opdivo in urothelial carcinoma
20 October 2017 - The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for ...
Posted by Michael Wonder on 16 Oct 2017
Roche’s skin cancer drug Erivedge pulled from CDF
13 October 2017 - Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute ...
Posted by Michael Wonder on 13 Oct 2017
Hundreds of patients to have access to head and neck cancer drug after new deal, says NICE
13 October 2017 - Nivolumab is recommended for use within the Cancer Drugs Fund for some patients with head and neck ...
Posted by Michael Wonder on 12 Oct 2017
New treatment option for people with gastro-intestinal cancer
12 October 2017 - More people will be able to receive regorafenib now that NICE has said it should move out ...